MedPath

Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19

Completed
Conditions
Covid-19
Registration Number
NCT04446286
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

Describes the cohort of patients receiving ECMO-VV or ECMO-VA in the management of severe ARDS refractory to SARS-CoV-2 in the Strasbourg and Louvain centres

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patient over the age of 18;
  • Diagnostic COVID-19 by RT-PCR;
  • Hospitalisation in resuscitation for the management of complications related to COVID-19
  • Implanted ECMO-VV or VA during hospitalisation;
  • Patient agreeing to participate in the study
Exclusion Criteria
  • Sujet who has expressed opposition to participating in the study.
  • Sujet under guardianship or trusteeship
  • Sujet under safeguard of justice

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Retrospective description of effect of the ECMO-VV or ECMO-VA in the management of severe ARDS refractory in patients of the Strasbourg and Louvain centres with covid-19files analysed retrospectily from March 1st, 2020 to August 1st, 2020 will be examined
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg

🇫🇷

Strasbourg, France

© Copyright 2025. All Rights Reserved by MedPath